Safety of rifabutin replacing rifampicin in the treatment of tuberculosis: A single-centre retrospective cohort study

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 3, 2014, Pages 790-796

  Chien, Jung Yien ^a,b   Chien, Shun Tien ^b   Huang, Szu Ying ^c   Yu, Chong Jen ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b Chest Hospital   (Taiwan)

^c Jianan Mental Hospital   (Taiwan)

Author keywords

Adverse reactions; Hepatitis; Neutropenia

Indexed keywords

RIFABUTIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; CHRONIC HEPATITIS C; COHORT ANALYSIS; COMPLICATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEPATITIS B; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; TUBERCULOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; COHORT STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIFABUTIN; RIFAMPIN; TUBERCULOSIS;

EID: 84894042593     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt446     Document Type: Article

References (23)

1. Dye C, Scheele S, Dolin P et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHOGlobal Surveillance and Monitoring Project. JAMA 1999; 282: 677-86.
2. World Health Organization, Stop TB Initiative (World Health Organization). Treatment of Tuberculosis: Guidelines. Geneva: World Health Organization, 2010.
3. Rifampin. Tuberculosis (Edinb) 2008; 88: 151-4.
4. Horne DJ, Spitters C, Narita M. Experience with rifabutin replacing rifampin in the treatment of tuberculosis. Int J Tuberc Lung Dis 2011; 15: 1485-9.
5. Jaramillo E, Stop TB Initiative (World Health Organization), Great Britain. Department for International Development et al. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis: [emergency update 2008]. Geneva: World Health Organization, Stop TB Department, 2008.
6. Marsili L, Pasqualucci CR, Vigevani A et al. New rifamycins modified at positions 3 and 4. Synthesis, structure and biological evaluation. J Antibiot (Tokyo) 1981; 34: 1033-8.
7. Grassi C, Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22 Suppl 1: S50-4.
8. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P et al. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Rifabutin Study Group. Tuber Lung Dis 1994; 75: 341-7.
9. Martinez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogeneticmechanisms, clinicalmanifestations,management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore) 1999; 78: 361-9.
10. Tattevin P, Revest M, Dupont M et al. A regimen containing rifabutin for the treatment of tuberculosis in patients intolerant to rifampin. Clin Infect Dis 2003; 36: 127-8.
11. Mancini P, Pasqua F, Mazzei L et al. Rifabutin treatment for tuberculosis patients with liver function abnormalities. J Antimicrob Chemother 1992; 30: 242.
12. Hsueh PR, Liu YC, So J et al. Mycobacterium tuberculosis in Taiwan. J Infect 2006; 52: 77-85.
13. Chien JY, Huang RM,Wang JY et al. Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Int J Tuberc Lung Dis 2010; 14: 616-21.
14. Marra F, Marra CA, Bruchet N et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis 2007; 11: 868-75.
15. McGregor MM, Olliaro P, Wolmarans L et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 154: 1462-7.
16. Ji B, Truffot-Pernot C, Lacroix C et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapyof tuberculosis in mice.AmRev Respir Dis 1993; 148: 1541-6.
17. Mitchison DA, Ellard GA, Grosset J. New antibacterial drugs for the treatment ofmycobacterial disease in man. Br Med Bull 1988; 44: 757-74.
18. Schluger NW. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients. Clin Infect Dis 1999; 28: 130-5.
19. De CianW, Sassella D, Wynne BA. Clinical experience with rifabutin in the treatmentofmycobacterial infections. ScandJ Infect DisSuppl1995;98:22-6.
20. Choong K, Looke D. Cross-reaction to rifabutin after rifampicin induced flu-like syndrome and thrombocytopenia. Scand J Infect Dis 2011; 43: 238.
21. Saukkonen JJ, Cohn DL, Jasmer RM et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-52.
22. Apseloff G, Fluids G, LaBoy-Goral L et al. Severe neutropenia caused by recommended prophylactic doses of rifabutin. Lancet 1996; 348: 685.
23. Tansey MJ, Moe JB. Severe neutropenia and prophylactic doses of rifabutin. Lancet 1996; 348: 1592-3.